우진비앤지

018620KOSDAQ의약품 제조업

55.9 / 100

Reference Date: 2026-07-24

Financial Score12.0 / 40

News Sentiment16.9 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Rose 8.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ujin B&G is a specialized company in animal pharmaceuticals, producing medications, vaccines, and supplements, with 35% of its sales coming from exports. Its subsidiaries, OSPI and Bawow Korea, manufacture pet food and treats, and the company aims to expand its market share through eco-friendly products and vaccine development.

Number of Employees

103people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

0.27Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE

-5.38Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

24.70Industry Average 12.430.5Point

2.0x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼2.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼25.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -4.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Positive
우진비앤지, 하반기 R&D·신규 시장 공략 나서
우진비앤지는 하반기 R&D 투자와 신규 시장 진출로 성장 동력 확보에 나서며 긍정적인 전망을 제시했다.
Neutral
오에스피, 24억원 규모 제3자배정 유상증자 결정
우진비앤지 관련 직접적인 영향 없음: 오에스피의 자금 조달 결정이 우진비앤지에 직접적인 영향을 미치지 않음.

Detailed Momentum

52-week position6.0Point

52w upper range (65%)

Current 2,445Won52-week high 3,40052-week low 670

1-month return5.0Point

1m +8.91% (rising)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-15
Neutral주식등의대량보유상황보고서(일반)2026-07-15
Neutral주식등의대량보유상황보고서(일반)2026-07-06